On November 4, Jazz Pharmaceuticals PLC rose 8.61% in Regular Trading, trading at $233.085 per share, with turnover of $119 million.

The move followed third-quarter results that topped revenue expectations and a higher full-year outlook, alongside an RBC price-target increase to $305 from $296 while maintaining an Outperform rating.

Jazz Pharmaceuticals PLC reported third-quarter revenue of $1.243 billion, up 10% year over year and above the roughly $1.208 billion market expectation. The company lifted full-year revenue guidance to $4.78 billion-$4.85 billion, above the approximately $4.73 billion consensus. Although adjusted EPS was a loss of $3.88, results were heavily affected by about $754 million-$755 million of in-process R&D charges tied to the Actio Biosciences acquisition; excluding that item, non-GAAP EPS was $7.15.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)